De Weger R A, Wilbrink B, Moberts R M, Mans D, Oskam R, Den Otter W
Cancer Immunol Immunother. 1987;24(1):25-36. doi: 10.1007/BF00199829.
We have studied the rather paradoxical phenomenon of the growth of an antigenic tumor in an immunocomponent host. This phenomenon was studied by comparing the lymphocyte reactivity and the macrophage cytotoxicity, during SL2 growth in DBA/2 mice (SL2-bearing mice) and in DBA/2 mice immunized against SL2 tumor cells (SL2-immune mice). Immune mice rejected a challenge of tumor cells. The immune T-lymphocytes rendered macrophages cytotoxic (arming) and were able to transfer tumor resistance to naive animals. Nonimmunized mice did not reject a challenge of SL2 cells. In these tumor-bearing mice various forms of immune reactivity were tested. Lymphocytes with the capacity to arm macrophages could not be found in the lymphoid organs. However, lymphocytes isolated from the tissue directly surrounding the subcutaneous SL2 tumor could arm macrophages in vitro. Shortly after subcutaneous tumor grafting cytotoxic macrophages were found in the peritoneal cavity. In the serum macrophage arming factors were detected that rendered macrophages cytotoxic in vitro. This cytotoxicity of the peritoneal macrophages and the presence of macrophage arming factors in the serum showed a similar biphasic pattern. The first phase of cytotoxicity between day 3 and 8 after tumor grafting was tumor (SL2) specific. The second phase from day 12 and onwards was not tumor specific. During the first 4 days after SL2 grafting the DBA/2 mice expressed a specific concomitant immunity to a second tumor graft. Then 7 or more days after grafting the first SL2 tumor, the concomitant immunity was nonspecific as the growth of a second SL2 tumor graft and a L5178Y (DBA/2) tumor graft were inhibited. In addition, the immune suppressive activity of serum and lymphocytes was tested. Neither serum nor lymphocytes from SL2-bearing mice suppressed the macrophage arming capacity of SL2 immune lymphocytes. Lymphocytes from tumor-bearing mice did not inhibit the capacity of SL2-immune lymphocytes to transfer resistance to naive animals. On the contrary, lymphocytes obtained from SL2-bearing mice 14 days after SL2 grafting transfered tumor resistance in a Winn-type assay. These data suggest that the growth of an antigenic tumor is due to the inability of the immune system to mount an effective antitumor effector cell population during tumor growth, rather than an immune suppression of the antitumor reactivity, as a limited immune reactivity could be detected in tumor-bearing mice, whereas immune suppression could not be detected.
我们研究了免疫功能正常的宿主中抗原性肿瘤生长这一颇为矛盾的现象。通过比较SL2在DBA/2小鼠(携带SL2的小鼠)和经SL2肿瘤细胞免疫的DBA/2小鼠(SL2免疫小鼠)体内生长期间的淋巴细胞反应性和巨噬细胞细胞毒性,对这一现象进行了研究。免疫小鼠能够排斥肿瘤细胞的攻击。免疫T淋巴细胞使巨噬细胞具有细胞毒性(武装),并能够将肿瘤抗性传递给未免疫的动物。未免疫的小鼠不能排斥SL2细胞的攻击。在这些荷瘤小鼠中测试了各种形式的免疫反应性。在淋巴器官中未发现具有武装巨噬细胞能力的淋巴细胞。然而,从皮下SL2肿瘤直接周围组织分离的淋巴细胞能够在体外武装巨噬细胞。皮下接种肿瘤后不久,在腹腔中发现了细胞毒性巨噬细胞。在血清中检测到巨噬细胞武装因子,其可使巨噬细胞在体外具有细胞毒性。腹腔巨噬细胞的这种细胞毒性以及血清中巨噬细胞武装因子的存在呈现出相似的双相模式。肿瘤接种后第3天至第8天的细胞毒性第一阶段是肿瘤(SL2)特异性的。从第12天及以后的第二阶段则不是肿瘤特异性的。在接种SL2后的前4天,DBA/2小鼠对第二次肿瘤接种表现出特异性伴随免疫。然后,在接种第一个SL2肿瘤7天或更长时间后,伴随免疫是非特异性的,因为第二次SL2肿瘤接种和L5178Y(DBA/2)肿瘤接种的生长均受到抑制。此外,还测试了血清和淋巴细胞的免疫抑制活性。来自荷瘤小鼠的血清和淋巴细胞均未抑制SL2免疫淋巴细胞的巨噬细胞武装能力。荷瘤小鼠的淋巴细胞未抑制SL2免疫淋巴细胞将抗性传递给未免疫动物的能力。相反,在SL2接种14天后从荷瘤小鼠获得的淋巴细胞在Winn型试验中传递了肿瘤抗性。这些数据表明,抗原性肿瘤的生长是由于免疫系统在肿瘤生长期间无法形成有效的抗肿瘤效应细胞群体,而不是对抗肿瘤反应性的免疫抑制,因为在荷瘤小鼠中可检测到有限的免疫反应性,而未检测到免疫抑制。